Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast
- Conditions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 18
- Registration Number
- NCT00473005
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer
- Conditions
- Interventions
- Drug: capecitabineDrug: oxaliplatinGenetic: gene expression analysisGenetic: microarray analysisGenetic: reverse transcriptase-polymerase chain reactionProcedure: adjuvant therapyProcedure: biopsyProcedure: conventional surgeryProcedure: neoadjuvant therapyProcedure: quality-of-life assessmentRadiation: radiation therapy
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00470184
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
- Conditions
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 330
- Registration Number
- NCT00469443
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT00468585
- Locations
- 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT00454636
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2010-07-12
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 33
- Registration Number
- NCT00453323
- Locations
- 🇰🇷
National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00452673
- Locations
- 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT00450515
Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Professor David Cunningham
- Target Recruit Count
- 1103
- Registration Number
- NCT00450203
- Locations
- 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Cumberland Infirmary, Carlisle, England, United Kingdom
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
- Conditions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 30
- Registration Number
- NCT00448552
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.